Cabergoline
7 NDCs across 7 manufacturers|7 Generic,0 Brand
Cabergoline is used to treat adenoma, hyperprolactinemia and parkinson disease, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Dec 23, 1996, and the first generic was approved Dec 29, 2005. FDA's Orange Book lists 6 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $7 million on Cabergoline across 90,000 claims for 22,000 beneficiaries.
Cabergoline is available as 7 NDCs from 7 manufacturers (7 generic, 0 brand), with NADAC prices from $1.30 to $1.30 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
7
7G / 0B
Manufacturers
7
competing in market
Price Spread
$1.30 – $1.30
per EA
7d Activity
avg -3.7% WoW · of 7 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Teva Pharmaceuticals USA Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Ergot Derivative class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
7 manufacturers producing CABERGOLINE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
CABERGOLINE 0.5 MG TABLET | $1.2952 per EA | -3.74% |
CABERGOLINE 0.5 MG TABLET | $1.2952 per EA | -3.74% |
CABERGOLINE 0.5 MG TABLET | $1.2952 per EA | -3.74% |
CABERGOLINE 0.5 MG TABLET | $1.2952 per EA | -3.74% |
CABERGOLINE 0.5 MG TABLET | $1.2952 per EA | -3.74% |
CABERGOLINE 0.5 MG TABLET | $1.2952 per EA | -3.74% |
CABERGOLINE 0.5 MG TABLET | $1.2952 per EA | -3.74% |
Frequently Asked Questions
What is Cabergoline used to treat?
Cabergoline is used to treat adenoma, hyperprolactinemia and parkinson disease, per the National Library of Medicine's MED-RT classification.
When did Cabergoline become available as a generic?
FDA approved the first generic Cabergoline (ANDA) on Dec 29, 2005. The Orange Book currently lists 6 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Cabergoline?
In 2024, Medicare Part D spent $7 million on Cabergoline across 90,000 claims for 22,000 beneficiaries.
How many Cabergoline products are on the market?
The Cabergoline drug market contains 7 NDCs from 7 manufacturers — 7 generic and 0 brand products.
What is the price range for Cabergoline?
NADAC reference prices for Cabergoline range from $1.2952 to $1.2952 per EA.
Which manufacturers make Cabergoline?
7 manufacturers list Cabergoline in NADAC. Ranked by number of NDCs, the largest are Teva Pharmaceuticals USA Inc. (1), Heritage Pharmaceuticals Inc. (1), Ingenus Pharmaceuticals LLC (1), Mylan Pharmaceuticals Inc. (1), Amneal Pharmaceuticals NY LLC (1).
How has the price of Cabergoline changed recently?
Over the past 7 days, 0 Cabergoline NDCs rose and 7 fell, with a market-wide average change of -3.7%.